This article was originally published in The Rose Sheet
Executive SummaryNatural fragrance watchdog Cropwatch "has no confidence" in the ability of the European Commission's Scientific Committee on Consumer Products (SCCP) to assess the possible safety risks of tea tree oil, the group says in a Jan. 17 statement, with the tea tree oil dossier up for the committee's review Jan. 22 based on data submitted by the Australian Tea Tree Oil Industries Association in March 2007. Cropwatch cites alleged flaws in a 2004 opinion from the panel, which concludes that undiluted tea tree oil is not safe to use in commercial products, the stability of the oil in cosmetic formulations is "questionable" and that further tests to determine skin and eye irritation - among other endpoints - should be conducted. The watchdog alleges that SCCP did not take into account all available scientific evidence on tea tree oil in its report and that the predictions of adverse events from use of the oil were exaggerated. "Cropwatch calls for a review of the way that cosmetic ingredient safety is assessed by the regulator, since the existing [overly] precautionary principled approach is clearly failing the public," the group states....
You may also be interested in...
Brands unfairly maligned by powerful influencers, strictly on behalf of paying competitors, could have occasion to broach the subject with the US Federal Trade Commission, which seeks comment on its “Endorsement Guides” in an increasingly complex and competitive, digitized advertising environment.
At least one FTC commissioner seems convinced that the agency’s Enforcement Guides are ripe for an update to address unscrupulous influencer marketing practices. Democrat Rohit Chopra proposes their codification into formal rules that would make violators liable for civil penalties and damages under FTC Act provisions.
The US agency has suspended all routine surveillance inspections in China through the end of March because of coronavirus fears, commissioner Stephen Hahn announced late on 14 February. Despite expecting medical product shortages, Hahn said the agency is being proactive: “We are not waiting for drug and device manufacturers to report shortages to us” before acting. The timing of Hahn’s statement – at 6 p.m. EST on a Friday, at the beginning of a three-day US holiday weekend – suggests he isn’t particularly excited to share the information.